Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 22 INR is left as net profit.
- Revenue grew by 14% a year over the last 3 years.
- Analysts expect revenue to grow by 18% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 77.2 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 18%. Earnings per share grew by 9.2% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 INR of revenue goes
- Cost of sales 25 INR
- Sales and administration 44 INR
- Taxes and other 9.1 INR
- Net profit 22 INR
Net profit, industry median (Medical - Diagnostics & Research) 8.8 INR
Out of every 100 INR of revenue, 22 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.14%
- Paid out of profit
- 11%
You receive ₹2.00 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail